Robert Langer

About Robert Langer

Robert Langer is a co-founder and scientific advisor at SUTOL Bio. The company develops a stomach-resident capsule that releases medicine continuously for more than a month. He is also the David H. Koch Institute Professor at MIT. He co-founded Syntis Bio, which develops treatments for obesity and rare diseases. He serves on Syntis Bio's board.

He joined MIT's faculty in 1978 and became an Institute Professor in 2006. He began consulting for Bioplex Systems, later T2 Biosystems, in 2006. Fibrocell appointed him to its board in September 2009. He was also a director of Alseres Pharmaceuticals and Echo Therapeutics. He also founded Teal Bio.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Robert Langer in the role, so the role may have started earlier or lasted longer.

Sutol Bio, Inc. Current

Co-Founder & Scientific Advisor, director

2026 – Present · Cambridge, MA

SUTOL Bio develops a stomach-resident capsule that releases medicine continuously for more than 30 days.

SB

Syntis Bio, Inc. Current

Director

2022 – Present · Boston, MA

MT

Massachusetts Institute of Technology Current

David H. Koch Institute Professor

SI

Seer, Inc.

Director

2020 – 2026 · Public company (SEER)

MI

Moderna, Inc.

Director

2018 – 2024 · Public company (MRNA)

TB

Teal Bio, Inc.

Director

2021 – 2023 · Somerville, MA

X

Xenter, Inc.

Director

2021 – 2023 · Draper, UT

KI

Korro Bio, Inc.

Director

2019 – 2022 · Public company (KRRO)

SB

SunBird Bio, Inc.

Director

2020 – 2021 · Cambridge, MA

SC

SQZ Biotechnologies Co

10% owner

2020 · Public company (SQZ)

LI

Lyra Therapeutics, Inc.

Director

2020 · Public company (LYRA)

RI

Rubius Therapeutics, Inc.

Director

2018 – 2019 · Public company (RUBY)

KI

Kala Bio, Inc.

Director and 10% owner

2017 – 2018 · Public company (KALA)

AC

Abpro Corp

Director

2018 · Public company (ABP)

DI

Dnib Unwind, Inc.

Director

2013 – 2016 · Public company (BIND)

CI

Cartesian Therapeutics, Inc.

10% owner

2016 · Public company (RNAC)

OI

Ocata Therapeutics, Inc.

Director

2012 – 2016 · Public company (OCAT)

IC

Invivo Therapeutics Holdings Corp.

10% owner

2010 – 2013 · Public company (NVIV)

FI

Fibrocell Science, Inc.

Director

2009 – 2011 · Public company (FCSC)

MC

Millipore Corp.

Director

2009 – 2010 · Public company (MIL)

EI

Echo Therapeutics, Inc.

Director

2006 – 2010 · Public company (ECTE)

WY

Wyeth

Director

2006 – 2009 · Public company (WYE)

AI

Alseres Pharmaceuticals Inc.

Director

2006 – 2009 · Public company (ALSE)

MI

Momenta Pharmaceuticals Inc.

Director

2006 – 2008 · Public company (MNTA)

BI

Bioplex Systems, Inc.

consultant

From 2006

Key Colleagues at Startups

The people Robert Langer works with at each company, as listed on that company's latest Form D.

Sutol Bio, Inc. · Form D, Nov 10, 2026

Seungho Lee

Co-Founder & CEO, director

Matt Murphy

Co-Founder & Chief Engineer, director

Carlo Traverso

Co-Founder & Scientific Advisor, director

Robert Langer in the News

• Jun 11, 2024·Boston Business JournalBob Langer startup Syntis Bio launches with GLP-1 drug ...
• Jun 11, 2024·SynBioBetaSyntis Bio Launches with $15.5M to Tackle Obesity and Rare Metabolic Diseases

Sources

1. SECSutol Bio, Inc. Form D, filed Nov 10, 2026
2. SECSyntis Bio, Inc. Form D, filed Jul 2, 2025
3. SECTeal Bio, Inc. Form D, filed Dec 27, 2023
4. SECXenter, Inc. Form D, filed Jan 6, 2023
5. SECSunBird Bio, Inc. Form D, filed Dec 17, 2021
6. SECForms 3, 4 and 5 filed by Robert Langer (SEC filer 1239757)
7. P2SUTOL Bio home and team page
8. P4Syntis Bio launch release
9. P7T2 Biosystems consulting agreement
10. P8Fibrocell Science director biography
11. S8Teal Bio Business Wire release snippet